Biomea Fusion, Inc. (BMEA) income statement

BMEANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30

$0.56−0.05 (-7.89%)

Close on Nov 12, 2026Market cap $40.79MP/E –Yield –

Biomea Fusion, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Research & Development	62	118	103	63	28	3.67	1.09
General & Administrative	19	26	24	21	14	1.66	0.10
Operating Expenses	84	144	126	84	42	5.33	1.20
Operating Income	-84	-144	-126	-84	-42	-5.33	-1.20
Asset Impairment Charges	2.21	0	0	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	–
Net Income incl. Noncontrolling Interests	-62	-138	-117	-82	-42	-5.32	-1.20
Net Income	-62	-138	-117	-82	-42	-5.32	-1.20
EPS (Basic)(per share)	-1.18	-3.83	-3.44	-2.80	-1.74	-0.51	-0.20
EPS (Diluted)(per share)	-1.18	-3.83	-3.44	-2.80	-1.74	-0.51	-0.20
Shares Outstanding (Basic, Weighted)(shares)	52	36	34	29	24	11	6.05
Shares Outstanding (Diluted, Weighted)(shares)	52	36	34	29	24	11	6.05
Net Interest Income	1.86	5.64	8.88	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -152.4%

Financial strength

Current ratio: 2.17
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 206.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 5.38
Dividend yield: –

See a number that looks wrong?